Evidence map›Paper›PMID 28656663›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2017

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination.

Xiaoli Wei, Jie Gao, Fei Wang, Man Ying, Pavimol Angsantikul, Ashley V Kroll, Jiarong Zhou, Weiwei Gao, Weiyue Lu, Ronnie H Fang and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Frontiers in microbiology · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Xiaoli WeiDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Jie GaoDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Fei WangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Man YingDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Pavimol AngsantikulDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Ashley V KrollDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Jiarong ZhouDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Weiwei GaoDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Weiyue LuDepartment of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Shanghai, 201203, P. R. China.
Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
University of California, San Diego · USMinistry of Education · KRFudan University · CN

Funding

Nanotherapeutics for Ocular InfectionsR01EY025947 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C, ZHANG, LIANGFANG · 2015 to 2017
$1.1M
Chemical Biology Interfaces at UC San DiegoT32GM112584 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2015 to 2019
$729k
NEI NIH HHS R01 EY025947NIGMS NIH HHS T32 GM112584
6 · The paper itself

Abstract

Antivirulence vaccination is a promising strategy for addressing bacterial infection that focuses on removing the harmful toxins produced by bacteria. However, a major challenge for creating vaccines against biological toxins is that the vaccine potency is often limited by lack of antigenic breadth, as most formulations have focused on single antigens, while most bacteria secrete a plethora of toxins. Here, a facile approach for generating multiantigenic nanotoxoids for use as vaccines against pathogenic bacteria by leveraging the natural affinity of virulence factors for cellular membranes is reported. Specifically, multiple virulent toxins from bacterial protein secretions are concurrently and naturally entrapped using a membrane-coated nanosponge construct. The resulting multivalent nanotoxoids are capable of delivering virulence factors together, are safe both in vitro and in vivo, and can elicit functional immunity capable of combating live bacterial infections in a mouse model. Despite containing the same bacterial antigens, the reported nanotoxoid formulation consistently outperforms a denatured protein preparation in all of the metrics studied, which underscores the utility of biomimetic nanoparticle-based neutralization and delivery. Overall this strategy helps to address major hurdles in the design of antivirulence vaccines, enabling increased antigenic breadth while maintaining safety.

Indexed as

AnimalsAntigensBacterial ToxinsDisease Models, AnimalMiceNanoparticlesVaccinationAntigensBacterial Toxinsantibiotic-resistant bacteriaantivirulence therapiesbiomimetic nanoparticlesnanomedicinevaccinations

Identifiers

PMID28656663
PMCPMC5581250
OpenAlexW2731526669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.